Semaglutide Reduces Heart Pressures in HFpEF with Obesity, Study Shows
Pessure Drops During Exercise
In people with obesity and heart failure with preserved ejection fraction, semaglutide reduced the pulmonary capillary wedge pressure during exercise by an average of 9.8 mmHg after 52 weeks, compared to an increase of 0.9 mmHg in the placebo group, according to research published November 8, 2026, in Nature Medicine.
- Semaglutide 2.4 mg weekly reduced left-sided heart filling pressures during physical exertion in a 52-week randomized trial of 81 participants.
- Hemodynamic remission, defined as pressures returning below set thresholds at rest and during exercise, occurred in 53.7% of treated participants versus 7.4% given placebo.
- European guidelines from late 2026 recommend evaluating kidney function and considering GLP-1 receptor agonists for specific clinical profiles involving chronic kidney disease, type 2 diabetes, and obesity-related heart conditions.
Semaglutide Reduces Exercise Pulmonary Capillary Wedge Pressure
The CAMEO-SEMA trial evaluated 81 participants, including 47 women, assigned randomly to receive either semaglutide at a weekly dose of 2.4 milligrams or a placebo for 52 weeks. Researchers utilized a catheter to measure pulmonary capillary wedge pressure, which estimates filling pressures in the left side of the heart.
Baseline measurements showed average pressures rising from 17.5 mmHg at rest to 31.7 mmHg during activity. After one year of treatment, exercise pressures dropped by an average of 9.8 mmHg in the semaglutide group, while the placebo group saw an increase of 0.9 mmHg.
The new drug showed a 10.6 mmHg lower average blood pressure than the placebo, with an additional 7.1 mmHg advantage at rest. Researchers also noted hemodynamic remission, defined as pressures returning below predetermined thresholds both at rest and during exercise, in 53.7% of treated participants compared to 7.4% of those receiving placebo. The term remission describes measurements returning within preset limits at that moment, rather than implying a complete clinical disappearance of heart failure.
Cardiac Imaging Shows Improved Heart Function
A second study published simultaneously in the same journal utilized cardiac magnetic resonance imaging on 49 participants from the CAMEO-SEMA trial, documenting improvements in left atrial function and left ventricular filling that correlated with reduced exercise pressures. These physiological observations build upon previous findings from the STEP-HFpEF trials, which showed reduced symptoms and improved walking capacity in individuals with obesity and preserved ejection fraction heart failure.
Broader regulatory and clinical developments provide additional context for the class of medications housing semaglutide. On October 3, 2025, Italy became the first country globally to legally recognize obesity as a chronic, progressive, and recidivante disease via law n.
149/2025. Subsequently, the European Society of Cardiology and the European Renal Association issued guidelines in late August 2026 linking cardiovascular disease and chronic kidney disease, recommending screening via estimated glomerular filtration rate blood tests and urine albumin-to-creatinine ratios.
Guidelines and Clinical Data Support Semaglutide Use
European guidelines indicate semaglutide for patients presenting with chronic kidney disease, type 2 diabetes, and albuminuria in combination with finerenone, and acknowledge GLP-1 receptor agonists for individuals with chronic kidney disease, obesity, and heart failure with preserved ejection fraction.
Major trial data supporting these applications include the FLOW study published in the New England Journal of Medicine, which showed a 24% reduction in major renal events among 3,533 participants with type 2 diabetes and chronic kidney disease treated with 1 mg of semaglutide weekly.
Despite these findings, researchers emphasize clear boundaries regarding the current data. The CAMEO-SEMA trial involved 81 participants observed for one year, representing a small randomized study primarily designed to assess hemodynamic parameters rather than reductions in hospitalizations, mortality, or definitive cures. Clinicians advise that semaglutide requires individual medical evaluation based on personal health risks rather than autonomous initiation.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.